Top Markets
Coin of the day
Bristol-Myers Squibb Company Bristol-Myers Squibb Company

Bristol-Myers Squibb Company

BMY
Rang in Aktien #174
Bristol-Myers Squibb Company operates as a global biopharmaceutical entity,... Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.
Aktienkurs
$62.26
Zuletzt synchronisiert: 2026-09-22
Marktkapitalisierung
$127.18B
Veränderung (1 Tag)
-0.78%
Veränderung (1 Jahr)
38.63%
Land
US
Handel Bristol-Myers Squibb Company (BMY)

Kategorie

Umsatz von Bristol-Myers Squibb Company (BMY)
Umsatz im Jun 2026 TTM: $49.19B
Laut den aktuellen Finanzberichten von Bristol-Myers Squibb Company beträgt der derzeitige Umsatz des Unternehmens (TTM) $49.19B. Im Jahr 2024 erzielte das Unternehmen einen Umsatz von $48.30B eine Steigerung gegenüber dem Umsatz im Jahr 2023, der $45.01B betrug. Der Umsatz ist der Gesamtbetrag, den ein Unternehmen durch den Verkauf von Waren oder Dienstleistungen erzielt. Im Gegensatz zum Gewinn werden keine Ausgaben abgezogen.
Umsatzverlauf für Bristol-Myers Squibb Company von 2000 bis 2026
Umsatz am Ende jedes Jahres
Jahr Umsatz ändert
2026 (TTM) $49.19B 2.06%
2025 $48.19B -0.22%
2024 $48.30B 7.32%
2023 $45.01B -2.50%
2022 $46.16B -0.49%
2021 $46.39B 9.09%
2020 $42.52B 62.62%
2019 $26.15B 15.89%
2018 $22.56B 8.59%
2017 $20.78B 6.94%
2016 $19.43B 17.31%
2015 $16.56B 4.29%
2014 $15.88B -3.09%
2013 $16.39B -7.01%
2012 $17.62B -17.05%
2011 $21.24B 9.03%
2010 $19.48B 3.59%
2009 $18.81B -8.69%
2008 $20.60B 6.46%
2007 $19.35B 8.00%
2006 $17.91B -6.73%
2005 $19.21B -0.89%
2004 $19.38B -7.25%
2003 $20.89B 15.32%
2002 $18.12B -6.71%
2001 $19.42B 6.63%
2000 $18.22B 0.00%
Umsatz vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Umsatz Umsatzunterschied Land
$79.67B 61.97%
US
$97.93B 99.10%
US
$64.39B 30.90%
US
$77.52B 57.60%
CH
$66.40B 35.00%
US